The top 20 pharma companies by 2021 revenue Workers at Cedars-Sinai, Stanford Health and Sutter Health eye labor strikes for more pay, safer staffing New antibiotics still a decade away unless policymakers, investors step up, AMR Action Fund CEO warns FDA says stroke-spotting AI hasn’t replaced doctors yet, urges providers to stay in the loop Novartis' global revamp to cost thousands of jobs for simpler structures: report White House seeks to clamp down on providers' predatory debt collection practices Aeglea's search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30% AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark Myovant, Pfizer's expansion bid for Myfembree hits a snag at the FDA Roche wins appeal to overturn $137M lab-testing patent infringement penalty Ansa Biotechnologies ties up $68M for DNA synthesis platform Insurtech unicorn Sidecar Health launches new group employer plan in Ohio Akili’s video game treatment for depression improves cognitive symptoms: study Featured Story | By Kevin Dunleavy 2021 was all about recovery from the COVID-19 pandemic. Several companies that quickly developed products to combat the coronavirus reaped huge profits, while others benefited simply from a return to more normalized business operations. Here's how the year shook out for the top 20 drugmakers by global revenues. read more |
| |
|---|
|
|
| Full-time Consulting Careers IPM is an industry leader in Life Sciences consulting and has managed projects for more than 150 biotech, pharma, and medtech companies. Learn how you can lead a variety of impactful projects with us. Explore here! |
Top Stories By Dave Muoio Cedars-Sinai, Stanford Health Care and Sutter Health have each been the recipient of new activity within the past few days. Nurses and healthcare workers across the California provider organizations are all calling for higher wages and safer workplace policies. read more By Gabrielle Masson Despite the growing threat posed by drug-resistant bacteria, new antibiotics may not reach the market for another decade, according to the head of a $1 billion fund tasked with seeking out solutions. read more By Conor Hale According to the agency, some healthcare providers may not be using these AI aids as intended when evaluating potential large-vessel occlusions. read more By Angus Liu Novartis is undertaking a huge restructuring to simplify its organization, and thousands of the employees will reportedly feel the pain. read more By Robert King HHS is calling for more than 2,000 providers to offer key information on their billing practices, with the information to be used to inform grantmaking decisions. read more By Nick Paul Taylor Aeglea BioTherapeutics’ bid to rehabilitate the battered reputation of its rare disease drug pegzilarginase has made early progress. Investors responded favorably to the presentation of additional phase 3 data, sending the stock up 21% in light of evidence the enzyme may act on clinical outcomes. read more By Annalee Armstrong Myelofibrosis is the cancer that keeps going and going—and AbbVie hopes new data from the phase 2 med navitoclax can make the case for stopping the rare and difficult-to-treat disease in its tracks. read more By Kevin Dunleavy Myovant and Pfizer’s application for Myfembree to treat endometriosis has hit a snag. In a letter to the companies, the FDA has identified deficiencies that “preclude discussion of labeling and/or post-marketing requirements and commitments at this time.” The combo drug was up for a May 6 decision. read more By Andrea Park Roche is getting a second chance in a long-running legal battle against Meso Scale Diagnostics. read more By Andrea Park Four years after its launch, Ansa has reeled in an oversubscribed series A funding round to roll out its enzymatic DNA synthesis platform. read more By Paige Minemyer The new group plans will be built on Sidecar's transparent pricing model, which also allows patients to see any doctor. In addition, members can also connect with the insurer's in-house Member Care team. read more By Andrea Park With the commercial rollout of its first prescription digital therapeutic for ADHD well underway, Akili Interactive is now turning its attention to other conditions that its particular brand of video game-based treatments could potentially address. read more |
